A new biomaterial scaffold, designed to slowly release stem cells, has worked to ensure implanted stem cells can stick around to relieve pain and reverse arthritis in mice knee joints.
This treatment reduces the quantity of stem cells needed by 90%, thus avoiding the problems of redness, swelling and scar tissue that can arise from large doses of such stem cells. In the near future, it could potentially lead to reversal of osteoarthritis in humans for the first time.
At present, no treatment is currently available that can reverse the course of osteoarthritis, and the sole options are to try to relieve pain. Stem cell therapy potentially offers hope and has been shown to alienate the disease. However, a ‘goldilocks’ dose of stem cells remains out of reach. Too much of a dose and the subject suffers redness, swelling and scar tissue. Too little and the therapy is only successful for a limited period due to gradual cell loss.
To overcome this challenge, researchers from the Department of Orthopedics at Huazhong University of Science and Technology, China, seeded umbilical cord mesenchymal stem cells on a ‘cryogel’ biomaterial.
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate themselves into other types of cells. MSCs are sourced from bone marrow, fat, or umbilical cord tissue. Umbilical cord-derived MSCs (UCMSCs) have emerged in recent years as popular therapeutic transplant cells due to their abundant supply, high proliferative capacity, and non-invasive harvesting procedure, and because they pose relatively minor ethical issues.
Cryogels, meanwhile, are gel matrices formed at sub-zero temperatures. They have interconnected macropores (pores larger than 10 micrometres in diameter), much like a sponge. Because these holes can allow mass transport of small particles in them, cryogel biomaterials potentially have a range of biomedical uses.
Continue reading… “3D biomaterial used as ‘sponge’ for stem cell therapy to reverse arthritis”
